Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
484 articles about Nektar Therapeutics
-
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
3/22/2024
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
-
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
3/5/2024
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
-
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
3/4/2024
Nektar Therapeutics today announced that it has entered into a securities purchase agreement with TCGX, an institutional accredited investor, to sell securities in a private placement financing (the "PIPE") for gross proceeds of $30 million, before deducting expenses.
-
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
2/27/2024
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
-
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
2/26/2024
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.
-
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
12/11/2023
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented a poster highlighting new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting.
-
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
11/7/2023
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023.
-
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
10/31/2023
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.
-
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
10/13/2023
Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at the 2023 European Academy of Dermatology and Venereology (EADV) Congress.
-
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
10/2/2023
Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin.
-
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
9/27/2023
Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBMG").
-
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
9/13/2023
Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b study. Rezpegaldesleukin is Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, which is being developed for the treatment of atopic dermatitis.
-
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
9/6/2023
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m. EST / 8:00 a.m. PST to discuss the final Phase 1b data of rezpegaldesleukin (REZPEG) in patients with atopic dermatitis, the atopic dermatitis treatment landscape, and the potential role of REZPEG, Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, in the treatment of atopic dermatitis.
-
Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More
8/11/2023
Novo’s weight-loss drug Wegovy improves cardiovascular outcomes, Novavax posts surprise Q2 profit, while Nektar Therapeutics files lawsuit against Eli Lilly for misconduct in drug development deal. -
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
8/8/2023
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023.
-
In a lawsuit filed Monday, Nektar Therapeutics accused Eli Lilly of scheming to ensure rezpegaldesleukin would not succeed after acquiring a competing medicine.
-
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
8/7/2023
Nektar Therapeutics announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly.
-
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
8/1/2023
Nektar Therapeutics will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-based financial markets.
-
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
6/12/2023
Nektar Therapeutics' senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 1:20 p.m. Pacific Time.
-
Nektar Therapeutics Reports First Quarter 2023 Financial Results
5/9/2023
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023.